Nordic Nanovector ASA -PARADIGME Update Transcript
Good morning, ladies and gentlemen. My name is Jan Egberts, I'm the Chairman of Nordic Nanovector. Together with me here are Erik Skullerud, our CEO; Malene Brondberg, our CFO.
Unfortunately, it's a very sad day for all of us today. Openly, we had to announce last night the discontinuation of the PARADIGME clinical study for Betalutin. So obviously, in particular, a sad day but not just exclusively for the shareholders who put a lot of money in the company, but also for the employees who worked very hard and also have invested a lot of their personal money in our company.
And finally, and probably even more importantly, the patients who had expected a very positive new treatment for this very deadly disease. So unfortunately, we had to discontinue the clinical study. We're going to share some data with you. Unfortunately, we cannot share everything at this stage. And the reason for that is that the guidelines by the FDA, the Food and Drug Administration, which is the U.S. regulatory authority. They don't
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
